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Simple Summary: Australia has one of the world’s highest breast cancer incidences. For most
women who are not classified as at high risk, eligibility and frequency of breast cancer screening in
Australia is based solely on their age. Breast cancer risk models can help to optimise early detection
and management of breast cancer. We evaluated six commonly used models over 15 years follow-up
using an Australian community-based cohort of 7608 women aged 50–65 years. The BOADICEA and
IBIS models best discriminated women who were at higher risk of developing breast cancer from
those at lower risk, but no model apart from BOADICEA accurately predicted absolute risk across
the risk spectrum. The BOADICEA model could be of clinical use for women of similar demography.
Abstract: Prospective validation of risk models is needed to assess their clinical utility, particularly
over the longer term. We evaluated the performance of six commonly used breast cancer risk models
(IBIS, BOADICEA, BRCAPRO, BRCAPRO-BCRAT, BCRAT, and iCARE-lit). 15-year risk scores were
estimated using lifestyle factors and family history measures from 7608 women in the Melbourne Col-
laborative Cohort Study who were aged 50–65 years and unaffected at commencement of follow-up
two (conducted in 2003–2007), of whom 351 subsequently developed breast cancer. Risk discrimi-
nation was assessed using the C-statistic and calibration using the expected/observed number of
incident cases across the spectrum of risk by age group (50–54, 55–59, 60–65 years) and family history
of breast cancer. C-statistics were higher for BOADICEA (0.59, 95% confidence interval (CI) 0.56–0.62)
and IBIS (0.57, 95% CI 0.54–0.61) than the other models (p-difference ≤ 0.04). No model except
BOADICEA calibrated well across the spectrum of 15-year risk (p-value < 0.03). The performance
of BOADICEA and IBIS was similar across age groups and for women with or without a family
history. For middle-aged Australian women, BOADICEA and IBIS had the highest discriminatory
accuracy of the six risk models, but apart from BOADICEA, no model was well-calibrated across the
risk spectrum.
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1. Introduction
Breast cancer is the most common cancer and cause of cancer death for women world-
wide, with approximately 2.3 million incident cases in 2020, and carries a substantial burden
of disease [1,2]. Australia and New Zealand have some of the highest age-standardised
incidence rates globally (95.5 per 100,000), twice the world average (47.8 per 100,000) [1].
Breast cancer risk models are currently used in familial cancer clinics by genetic
counsellors to stratify women and inform risk-tailored advice on the optimal age range,
frequency, and modality of screening for those at high risk [3,4]. For most women who are
not classified as high-risk, eligibility and frequency of breast cancer screening in Australia
is based solely on age. Risk models that incorporate pertinent risk factors that are easily ob-
tained from questionnaires, including a woman’s breast cancer family history and lifestyle
factors, may provide valuable information for this group of women to optimise early
detection and management. Previously, we demonstrated the potential for two models
(International Breast Cancer Intervention Study model (IBIS) and the breast and ovarian
analysis of disease incidence and carrier estimation algorithm model: BOADICEA) to
estimate 10-year risks using an Australian prospective cohort study [5]. Other commonly
applied and validated risk models exist (the breast cancer risk assessment tool (BCRAT) [6],
individualised coherent absolute risk estimators—literature model (iCARE-lit) [7], and
BayesMendel (BRCAPRO and BRCAPRO-BCRAT) [8]), but there is a lack of studies com-
paring their performance, particularly over longer follow-up durations (>10 years), which
is important for individual and population health care planning for conditions that have a
long lead time [9]. We therefore aimed to evaluate and compare 15-year risk estimates for
developing breast cancer across these six risk models.
2. Materials and Methods
2.1. Study Design and Participants
The Melbourne Collaborative Cohort Study (MCCS) is a prospective cohort that
includes 24,469 women from Melbourne, Australia, aged between 27 and 76 years (99%
were 40–69 years) at recruitment [10]. All participants were of White European descent,
including 8% born in Italy, 6% in Greece, and 8% in the UK/Malta with the rest born in
Australia or New Zealand in our final sample. They attended baseline (1990–1994) and
up to two waves of active follow-up in 1995–1998 and 2003–2007. Our analyses included
women who were aged 50–65 years (with 65 years being the maximum age for 15-year
risk estimation by age 80 years) when they attended follow-up 2 (2003–2007; designated
as the start of follow-up for this analysis), since follow-up 2 had the most complete data
on family history available. Women were eligible if they had completed the baseline and
follow-up 2 questionnaires and had no prevalent breast or ovarian cancer prior to their
follow-up 2 visit. The final sample used to evaluate models for 15-year risk of breast cancer
consisted of 7608 women, 351 of whom were diagnosed with a first invasive breast cancer
within 15 years after their follow-up 2 visit. For comparison, we also evaluated the models
for their 5-year and 10-year risks. MCCS participants provided informed consent, and the
Cancer Council Victoria Human Research Ethics Committee approved the study [10].
2.2. Risk Assessment
We used the latest versions (at the time of analysis) of the risk models: BOADICEA
version 5.0.0, using updated Australian incidence rates [11]; IBIS version 8b [12]; BCRAT
version 4.1 [6]; iCARE-lit version 1 [7]; and BRCAPRO and BRCAPRO-BCRAT version
2.1–7 [8]. These models varied in their underlying age-specific incidences of breast cancer,
and input variables (Supplementary Table S1).
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At follow-up 2, MCCS participants completed a questionnaire that asked about their
demographic characteristics and lifestyle-related factors, including, for example, age, alco-
hol intake, age at menarche, parity, number of sisters, brothers, and children, age at first
birth, menopausal status, and use of the oral contraceptive pill and menopausal hormone
therapy. Summary family history data on affected relatives were obtained from question-
naires at follow-up 2 (first-degree relatives) and follow-up 1 (second-degree relatives).
Data from the most recent questionnaires were used and supplemented with that from
older questionnaires if unavailable. To reconstruct pedigrees, the following assumptions
were made about the year of birth (YOB) of participants’ relatives: mothers and aunts
(25 years before the participant’s YOB), grandmothers (50 years before the participant’s
YOB), sisters (participant’s YOB), and daughters (25 years after the participant’s YOB).
Missing ages for affected and unaffected mothers, aunts, and grandmothers were imputed
to 70 years, whereas for sisters, they were imputed to the youngest of the participants’ age
at follow-up 2 or aged 70 years (except for BRCAPRO and BRCAPRO-BCRAT, where the
software imputed missing ages). Weight at follow-up 2 was measured to the nearest 100 g
using a digital electronic scale, while height was measured at baseline to the nearest 1 mm,
using a stadiometer. Body mass index (BMI) was defined as weight (kg) divided by height
squared (m2). History of hyperplasia or benign breast disease were not available. As our
aim was to compare models using solely family history and lifestyle risk factor information,
results from germline genetic testing for pathogenic variants in BRCA1 and BRCA2 (or
susceptibility genes) and mammographic density were not included in our analyses due to
lack of availability of these data for most women.
2.3. Outcome Assessment
Incident cases and vital status were ascertained from record linkage between the
Victorian Cancer Registry, the Victorian Registry of Births, Deaths, and Marriages, the
National Death Index, and the Australian Cancer Database. Cases were notified to the
Victorian Cancer Registry with a first diagnosis of invasive breast cancer (3rd Revision of
the International Classification of Diseases for Oncology code C50) during follow-up to
1 March 2019.
2.4. Statistical Analysis
Follow-up began at follow-up 2 attendance and ended at: (i) diagnosis of invasive
breast cancer, (ii) follow-up time reaching 15 years, (iii) age 80 years (maximum age for
estimating risk in BOADICEA), or (iv) censor date of 1 March 2019, whichever came first.
Expected cancer counts for the defined cohort were estimated for each model by summing
the predicted risks over all eligible participants. Deaths from causes other than breast
cancer were included as competing risks for all models except for two, BOADICEA and
BRCAPRO-BCRAT, because they do not currently have an option to account for competing
causes of death.
We compared the performance of the models with up to 15-year risk in terms of
discrimination and calibration. Calibration was assessed by comparing the number of
expected cases (E) within the cohort with the number observed (O). Model discrimination
was assessed using a concordance statistic (C-statistic) [13] and plotting receiver operating
characteristic (ROC) curves, accounting for incomplete follow-up, where 1 indicates perfect
discrimination and 0.50 indicates discrimination no better than chance.
The assessment of model calibration at the individual level was graphically repre-
sented from the model’s goodness of fit using the calibration belt routine. This method
uses likelihood-based tests on a data-driven forward selection of polynomial regression
models to assess the goodness of fit of the 15-year risk estimates from the six models, where
a p-value < 0.05 indicates miscalibration [14]. Calibration by quintiles of 15-year risk were
also plotted [15]. Model calibration and discrimination were also examined stratified by
age (50–54, 55–59 and 60–65 years) and by whether the women had an affected first- or
second-degree relative. We also examined model performance for 5-year and 10-year risk.
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Sensitivity analysis included additional censoring at diagnosis of ductal carcinoma in situ.
Analyses were performed using Stata (version 16) and R (version 3.6.1).
3. Results
The study sample consisted of 7608 Australian women with a mean age of 58.5 years
and mean BMI of 27.2 kg/m2; 23% had a first- or second-degree family history of breast can-
cer (Table 1). The six risk models have different input variables (Supplementary Table S1)
and predicted risk distribution (Supplementary Figure S1). IBIS and BOADICEA had the
widest range of predicted-risk distribution.
Table 1. Characteristics of the Melbourne Collaborative Cohort Study participants (aged 50–65 years).
Characteristics Mean SD
Age (years) 58.5 4.3
Height (cm) 162.0 6.6
Weight (kg) 71.3 13.9
BMI (kg/m2) 27.2 5.3
Alcohol intake (ethanol g/d) 8.9 11.9
Menarche age (years) 12.9 1.6
Number of live births 2.1 1.4
Age at first birth (years) 25.4 4.8
Age of menopause (years) 1 49.5 4.8
Incidence of breast cancer per 1000 person-years 2 3.35 (95% CI: 3.01, 3.72)










Unable to determine 1608 21.1
Menopausal hormone therapy use 4
Never 3848 50.6
Former 1643 21.6
Current Oestrogen 121 1.6
Current Oestrogen and Progesterone 752 9.9
Current hormone replacement therapy type missing 477 6.3
Missing 5 767 10.1
Family history of breast cancer 6
No 5888 77.4
Yes 1720 22.6
Sample size: 351 cases, 7608 total participants; 1 Women whose reasons for periods stopping were due to having
had a natural menopause or a bilateral oophorectomy; 2 Standardised incidence rate; 3 Postmenopausal is defined
as: had menstrual period in last 12 months and currently using HRT (or missing) and aged at least 55 years; or no
menstrual period in last 12 months (or missing) and periods stopped naturally; or no menstrual period in last
12 months (or missing) and periods stopped because ovaries were removed and two ovaries were removed; or
no menstrual period in last 12 months (or missing) and periods stopped due to hysterectomy/other reason (or
missing) and aged at least 55 years. 4 Type of hormone replacement therapy based on assumption of oestrogen
for those who have had a hysterectomy and combined oestrogen and progesterone for those on HRT but have
not had a hysterectomy. 5 Women in this category included those that were not asked or those where former use
(between follow-up 1 and 2) could not be fully confirmed. 6 Family history in first- or second-degree relatives. SD:
standard deviation; BMI: body mass index; cm: centimetres; kg: kilogram; g/d: grams/day.
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The overall discrimination of 15-year breast cancer risk (measured by C-statistic) across
the six models ranged between 0.51 and 0.59 (Table 2; Figure 1). IBIS and BOADICEA had
higher discriminatory accuracy than the other four models; C-statistics were 0.57 (95%
confidence interval (CI): 0.54,0.61) and 0.59 (95%CI: 0.56,0.62), respectively (p-difference
compared with the other four models ≤0.04). C-statistics did not vary significantly across
different age subgroups, whereas C-statistics from all models (except for BCRAT) were
slightly higher for women who had a family history of breast cancer than for those who
did not have any affected relatives.
Overall summary measures of calibration showed that BRCAPRO and BRCAPRO-
BCRAT overestimated risk (both E/O = 1.11, 95% CI: 1.00,1.23) (Table 2), particularly for
those aged 60–65 years. Across the full spectrum of predicted risks, all models except
for BOADICEA showed evidence of miscalibration (p-value < 0.03), where they generally
underpredicted risk at the low end of risk and overpredicted risk at high end of risk
(Figure 2).
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Figure 1. Receiver operating characteristic curves for six risk models. C-statistics are denoted in
brackets. The dotted line denotes represents the line of no discrimination.
Findings were similar for 5-year and 10-year risk of breast cancer, except that only
BCRAT and iCARE-lit showed evidence of miscalibration with 5-year risk (p-value < 0.02),
whilst iCARE-lit had higher discrimination at 5-year and 10-year risk compared with
15-year risk (Table 3; Supplementary Figures S2 and S3). Sensitivity analysis that included
censoring for in situ breast cancer (91 cases) gave similar discrimination and calibration
results (Supplementary Table S2).
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Table 2. Calibration and discrimination of 15-year risks for six breast cancer risk models.










IBIS 341.5 351 0.97 (0.88,1.08) 0.57 (0.54,0.61)
BOADICEA 342.4 351 0.98 (0.88,1.08) 0.59 (0.56,0.62)
BRCAPRO 389.3 351 1.11 (1.00,1.23) 0.51 (0.48,0.54)
BRCAPRO-BCRAT 389.7 351 1.11 (1.00,1.23) 0.51 (0.48,0.54)
BCRAT 327.9 351 0.93 (0.84,1.04) 0.54 (0.51,0.57)
iCARE-lit 339.5 351 0.97 (0.87,1.07) 0.53 (0.50,0.56)
Age 50–54 years 1912
IBIS 90.0 91 0.99 (0.81,1.21) 0.59 (0.53,0.65)
BOADICEA 82.9 91 0.91 (0.74,1.12) 0.60 (0.54,0.66)
BRCAPRO 82.7 91 0.91 (0.74,1.12) 0.49 (0.43,0.55)
BRCAPRO-BCRAT 82.8 91 0.91 (0.74,1.12) 0.49 (0.43,0.55)
BCRAT 76.1 91 0.84 (0.68,1.03) 0.54 (0.48,0.60)
iCARE-lit 85.7 91 0.94 (0.77,1.16) 0.55 (0.49,0.62)
Age 55–59 years 2679
IBIS 122.1 116 1.05 (0.88,1.26) 0.56 (0.50,0.61)
BOADICEA 124.2 116 1.07 (0.89,1.28) 0.59 (0.54,0.65)
BRCAPRO 134.9 116 1.16 (0.97,1.39) 0.54 (0.49,0.59)
BRCAPRO-BCRAT 135.0 116 1.16 (0.97,1.40) 0.54 (0.49,0.59)
BCRAT 114.7 116 0.99 (0.82,1.19) 0.58 (0.53,0.63)
iCARE-lit 120.4 116 1.04 (0.86,1.24) 0.51 (0.46,0.57)
Age 60–65 years 3017
IBIS 129.4 144 0.90 (0.76,1.06) 0.58 (0.53,0.63)
BOADICEA 135.4 144 0.94 (0.80,1.11) 0.59 (0.54,0.64)
BRCAPRO 171.8 144 1.19 (1.01,1.40) 0.51 (0.46,0.56)
BRCAPRO-BCRAT 171.9 144 1.19 (1.01,1.41) 0.49 (0.44,0.54)
BCRAT 137.2 144 0.95 (0.81,1.12) 0.51 (0.46,0.56)
iCARE-lit 133.5 144 0.93 (0.79,1.09) 0.55 (0.50,0.60)
No family history of
breast cancer 1 5888
IBIS 217.7 241 0.90 (0.80,1.02) 0.54 (0.50,0.58)
BOADICEA 241.1 241 1.00 (0.88,1.13) 0.56 (0.52,0.59)
BRCAPRO 300.5 241 1.25 (1.10,1.41) 0.50 (0.46,0.54)
BRCAPRO-BCRAT 300.7 241 1.25 (1.10,1.42) 0.50 (0.46,0.54)
BCRAT 229.8 241 0.95 (0.84,1.08) 0.53 (0.49,0.56)
iCARE-lit 255.4 241 1.06 (0.93,1.20) 0.52 (0.48,0.56)
Family history of
breast cancer 1 1720
IBIS 123.8 110 1.13 (0.93,1.36) 0.57 (0.52,0.62)
BOADICEA 101.4 110 0.92 (0.76,1.11) 0.60 (0.55,0.65)
BRCAPRO 88.8 110 0.81 (0.67,0.97) 0.53 (0.47,0.58)
BRCAPRO-BCRAT 89.0 110 0.81 (0.67,0.97) 0.52 (0.47,0.58)
BCRAT 98.2 110 0.89 (0.74,1.08) 0.52 (0.46,0.57)
iCARE-lit 84.2 110 0.77 (0.63,0.92) 0.53 (0.47,0.59)
1 Family history in first- or second-degree relatives. IBIS: International Breast Cancer Intervention Study model (IBIS or Tyrer-Cuzick
version 8b); BOADICEA: the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm model (version 5.0.0);
BRCAPRO: BayesMendel (version 2.1-7); BRCAPRO-BCRAT (version 2.1-7); BCRAT: the Breast Cancer Risk Assessment Tool (version 4.1);
iCARE-lit: Individualised Coherent Absolute Risk Estimators—literature model (version 1); MCCS: Melbourne Collaborative Cohort Study;
CI: confidence interval.
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Table 3. Calibration and discrimination statistics for 5-year, 10-year, and 15-year risk.










IBIS 121.8 124 0.98 (0.82,1.17) 0.57 (0.54,0.61)
BOADICEA 118.4 124 0.95 (0.80,1.14) 0.59 (0.56,0.62)
BRCAPRO 119.7 124 0.97 (0.81,1.15) 0.51 (0.48,0.54)
BRCAPRO-BCRAT 119.8 124 0.97 (0.81,1.15) 0.51 (0.48,0.54)
BCRAT 111.1 124 0.90 (0.75,1.07) 0.54 (0.51,0.57)
iCARE-lit 181.6 124 1.46 (1.23,1.75) 0.59 (0.56,0.62)
10-year risk 7608
IBIS 245.7 252 0.97 (0.86,1.10) 0.58 (0.54,0.61)
BOADICEA 237.6 252 0.94 (0.83,1.07) 0.59 (0.56,0.62)
BRCAPRO 260.9 252 1.04 (0.92,1.17) 0.51 (0.48,0.54)
BRCAPRO-BCRAT 261.1 252 1.04 (0.92,1.17) 0.51 (0.48,0.54)
BCRAT 230.6 252 0.92 (0.81,1.04) 0.54 (0.51,0.57)
iCARE-lit 290.6 252 1.15 (1.02,1.30) 0.58 (0.55,0.61)
15-year risk 7608
IBIS 341.5 351 0.97 (0.88,1.08) 0.57 (0.54,0.61)
BOADICEA 342.4 351 0.98 (0.88,1.08) 0.59 (0.56,0.62)
BRCAPRO 389.4 351 1.11 (1.00,1.23) 0.51 (0.48,0.54)
BRCAPRO-BCRAT 389.7 351 1.11 (1.00,1.23) 0.51 (0.48,0.54)
BCRAT 327.9 351 0.93 (0.84,1.04) 0.54 (0.51,0.57)
iCARE-lit 339.5 351 0.97 (0.87,1.07) 0.53 (0.50,0.56)
IBIS: International Breast Cancer Intervention Study model (IBIS or Tyrer-Cuzick version 8b); BOADICEA: the Breast and Ovarian Analysis
of Disease Incidence and Carrier Estimation Algorithm model (version 5.0.0); BRCAPRO: BayesMendel (version 2.1-7); BRCAPRO-
BCRAT (version 2.1-7); BCRAT: the Breast Cancer Risk Assessment Tool (version 4.1); iCARE-lit: Individualised Coherent Absolute Risk
Estimators-literature model (version 1); MCCS: Melbourne Collaborative Cohort Study; CI: confidence interval.
4. Discussion
Of the six risk models assessed over a 15-year follow-up period in an Australian cohort
of 7608 women, IBIS and BOADICEA showed superior discrimination between cases and
non-cases compared with the other four models. All models except for BOADICEA showed
evidence of miscalibration across the risk spectrum.
Models that include multigenerational family history (IBIS, BOADICEA) had the
widest range of predicted risk distribution. The exceptions to this wider predicted risk
distribution by pedigree-based models were the two BRCAPRO models, likely because
they only allow for the effects of BRCA1 and BRCA2 pathogenic variants in modelling
familial relative risk, thus substantially underestimating the contribution of family history
to the disease risk [14]. Interestingly, the predicted-risk distribution of BRCAPRO-BCRAT
remained closer to BRCAPRO than BCRAT, probably because it adopts the same approach
as BRCAPRO to estimate risk from family history. On the other hand, the risk estimated
from BCRAT is not dependent on the likelihood of being a BRCA1 or BRCA2 mutation
carrier, and the relative risks attributed to family history of breast cancer remain constant
with age of the consultee.
A previous study that analysed a combined Australian and North American cohort
reported higher 10-year C-statistics for BCRAT (0.64), BRCAPRO (0.62), IBIS (0.66), and
BOADICEA (0.65) [9]. This may be due to the study sample having a higher underly-
ing risk, given that they were recruited from breast cancer family registries and had a
much wider age range. Interestingly, in our stratified analysis for 15-year risk, we noted
slightly higher C-statistics for those with a family history of breast cancer (Table 2) for
all models except BCRAT. Similar measures of discrimination (area under the receiver
operating characteristic curves (AUCs)) were reported for 6-year breast cancer risk within
an American screening cohort aged 50 years or older for IBIS (0.60), but they detected
higher AUCs for BCRAT (0.61) and BRCAPRO (0.58) [15]. It is unlikely that the lower
discrimination results observed for BCRAT and the BRCAPRO models in our study were
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due to using underlying USA incidence rates (there was no option to select Australian
rates); we observed virtually no difference in results when selecting Australian or USA
incidence rates for the BOADICEA model (data not shown). The American study noted
a similar overprediction using BRCAPRO for those without a family history of breast
cancer and underprediction for those with >2 first/second degree family members [15].
Our estimated discriminatory ability for iCARE-lit was similar to that from a study of 15
international average-risk cohorts (including the MCCS), which reported a 5-year risk area
under the ROC curve of 0.57 [7]. That study reported an underestimation of breast cancer
for MCCS participants in the highest decile of 5-year risk using iCARE-lit [7], whereas
we detected an overestimation of breast cancer risk in the highest quintile for 5-year risk
(Supplementary Figure S2). The previous study, however, had used MCCS baseline data;
thus, it was less contemporary, participants were younger on average, and detailed family
history information was not collected at baseline. A systematic review of validation studies
of models including IBIS and BCRAT using average risk women outside of Australia have
shown comparable moderate discriminatory accuracy [16].
IBIS and BOADICEA consistently outperformed other risk models in discrimina-
tion, including in family registries that encompass participants from Australia, USA, and
Canada [9]. We show that their discriminatory performance is consistent over short and
long periods of follow-up (5, 10, and 15 years) (Table 3). Additionally, calibration across
different categories of predicted risk appeared relatively stable for BOADICEA when
comparing 5-year, 10-year, and 15-year risk estimates. On the other hand, IBIS showed
evidence of miscalibration for 10-year and 15-year risk. Results presented here on the cali-
bration and discriminatory ability of the models could be used to determine the use of such
models for long-term health planning, but clinicians should bear in mind the purpose and
audience when deciding the most appropriate timeframe to estimate risk [17]. Women of
child-bearing age may find shorter periods (e.g., 5-year) helpful when considering risk mit-
igation behaviours or therapy (e.g., mastectomy) that may affect family planning, whereas
longer-term risk estimations (e.g., 15-year) may be useful for women at higher risk seeking
earlier prevention [17]. Thus far, validation of risk estimates beyond 10 years has been
limited by a lack of studies with long-term follow-up, so our findings fill a gap to support
expansion of the clinical utility of BOADICEA and further evaluation of other models.
We have previously demonstrated a doubling of discriminatory accuracy for IBIS
and BOADICEA (C-statistic from 0.56–0.57 to 0.62) with the addition of a polygenic risk
score to predictors examined (age, family history, and lifestyle factors) using a subsample
of the MCCS [5]. These results were also in line with published data from the UK [18].
Additionally, Nguyen and colleagues used an agnostic approach to predict breast cancer
with mammographic imaging and showed similar improvements in discrimination (AUC
0.63) [19]. Although the study samples are not directly comparable, this supports the
view that the performance of risk models will be enhanced by the inclusion of input
variables such as common genetic susceptibility variants and mammographic imaging-
based measures.
5. Conclusions
We evaluated six breast cancer risk models within an Australian average-risk cohort
of women aged 50 to 65 years and found that IBIS and BOADICEA had the highest dis-
criminatory accuracy and that their discriminatory accuracy remained consistent over
time. However, apart from BOADICEA, no model was well-calibrated across the risk spec-
trum. Breast cancer risk models can help strengthen preventive efforts such as screening
programs for average-risk Australian women via tailored surveillance advice. Models
with lifestyle-related factors and family history will further benefit from the inclusion of
information on genetics and mammographic density.
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